Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expanded Indication For Edwards’ Sapien 3 Squarely In Sight

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences is on track to earn an expanded indication for its Sapien 3 transcatheter aortic valve replacement (TAVR) system – possibly earlier than expected – as the Sapien 3 observational study shows that patients deemed to be at intermediate risk for surgical complications may have better one-year outcomes with the TAVR system than surgical valve replacement.


Related Content

ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve
Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH
OUS Approvals Analysis: Edwards, Medtronic, Ra Medical Headline A Very Slow Month For Non-US Approvals
OUS Approvals Analysis: BSX, Edwards Score New CE Marks In TAVR Battlefield; Chinese DES Advances In Asia
OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks
US FDA Approves First Intermediate-Risk Indication For TAVR
FDA Approves Edwards' Rapid-Deployment Minimally Invasive Surgical Valve





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts